TY - JOUR
T1 - Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project
AU - Boada, Mercè
AU - Rodrigo, Adrián
AU - Jessen, Frank
AU - Wimblad, Bengt
AU - Kramberger, Milika
AU - Visser, Pieter Jelle
AU - Simó, Rafael
AU - Rodríguez-Gomez, Octavio
AU - Ciudin, Andreea
AU - Georges, Jean
AU - Dumas, Annete
AU - the MOPEAD consortium
AU - Maguire, Peggy
AU - Krivec, David
AU - Wimo, Anders
AU - Valero, Sergi
AU - Alegret, Montserrat
AU - Jamilis, Laura
AU - Zwan, Marissa
AU - Sannemann, Lena
AU - Arrufat, Jordi
AU - Stomrud, Erik
AU - Johansson, Gunilla
AU - Shering, Craig
AU - Glaysher, Bridget
AU - Stewart, Neil
AU - Belger, Mark
AU - Iradier, Fatima
AU - Campo, Laura
N1 - Funding Information: Laura Campo a full‐time employee of Eli Lilly Italia S.p.A. and shareholder of Eli Lilly. Frank Jessen has received consulting fees from Abbvie, AC‐Immune, Biogen, Danone/Nutricia, Eisai, Green Valley, Grifols, Janssen, MSD, Roche, and Vifor and has participated in advisory boards for AC Immune. Bengt Wimblad has participated in advisory boards for Alzinova, Axon Neuroscience, Biogen, and Resverlogix. Mercè Boada has received consulting fees from Biogen, Roche, and Merck. Fundació ACE has received funding from Grifols, Cortexmy, Abbvie, and Zambon. Peggy Maguire has received honoraria from University of Lodz (Poland). Anders Wimo has received funding/consulting fees from Eli Lilly, MSD, Eisai/Pfizer, Biogen, and Gates Ventures. Pieter Jelle Visser has received research grants from ZonMW, IMI, and Biogen and consulting fees from Synapsis. Rafael Simó has received research grants from Novo Nordisk, Roche, OM pharma, Abbott, Air liquid, and Lilly. Craig Shering is an AstraZeneca employee and receives AstraZeneca stock as part of his remuneration. All other authors report no conflict of interests. Funding Information: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115985. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation program and the European Federation of Pharmaceutical Industries and Associations. www.imi.europa.eu/ . All participants provided informed consent. Publisher Copyright: © 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Introduction: The Models of Patient Engagement for Alzheimer's Disease (MOPEAD) project was conceived to explore innovative complementary strategies to uncover hidden prodromal and mild Alzheimer's disease (AD) dementia cases and to raise awareness both in the general public and among health professionals about the importance of early diagnosis. Methods: Four different strategies or RUNs were used: (a) a web-based (WB) prescreening tool, (2) an open house initiative (OHI), (3) a primary care–based protocol for early detection of cognitive decline (PC), and (4) a tertiary care–based pre-screening at diabetologist clinics (DC). Results: A total of 1129 patients at high risk of having prodromal AD or dementia were identified of 2847 pre-screened individuals (39.7%). The corresponding proportion for the different initiatives were 36.8% (WB), 35.6% (OHI), 44.4% (PC), and 58.3% (DC). Conclusion: These four complementary pre-screening strategies were useful for identifying individuals at high risk of having prodromal or mild AD.
AB - Introduction: The Models of Patient Engagement for Alzheimer's Disease (MOPEAD) project was conceived to explore innovative complementary strategies to uncover hidden prodromal and mild Alzheimer's disease (AD) dementia cases and to raise awareness both in the general public and among health professionals about the importance of early diagnosis. Methods: Four different strategies or RUNs were used: (a) a web-based (WB) prescreening tool, (2) an open house initiative (OHI), (3) a primary care–based protocol for early detection of cognitive decline (PC), and (4) a tertiary care–based pre-screening at diabetologist clinics (DC). Results: A total of 1129 patients at high risk of having prodromal AD or dementia were identified of 2847 pre-screened individuals (39.7%). The corresponding proportion for the different initiatives were 36.8% (WB), 35.6% (OHI), 44.4% (PC), and 58.3% (DC). Conclusion: These four complementary pre-screening strategies were useful for identifying individuals at high risk of having prodromal or mild AD.
KW - Alzheimer's disease
KW - diagnostic gap
KW - early diagnosis
KW - patient engagement
KW - population-based screening
UR - http://www.scopus.com/inward/record.url?scp=85111692154&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/alz.12441
DO - https://doi.org/10.1002/alz.12441
M3 - Article
C2 - 34310061
SN - 1552-5260
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
ER -